Molnar-Institute - Pharma Technology Focus | Issue 115 | February 2022

DryLab^®4: Empower™ Automated.

One-Click Batch Creation. Enhanced Modeling Performance

The 4-Step Design Space Modeling Workflow

Waters Empower™ + Instrumentation

Waters Empower™ + Instrumentation

Design Space Modeling in 4 Simple Steps

Empower Automated

DryLab. Chromatographic Retention Modeling since 1986

02/24/2024 12:26:14

Home | Mapping the RNA therapeutics R&D landscape in 2022
In this issue
Contents
CSafe Global
Briefing
Industry news
The pharma industry briefing
Covid-19 executive briefing by GlobalData
HOF Sonderanlagenbau
BEA Technologies
Comment
Restrictive Medicare coverage spells continued uncertainty for Aduhelm
2021: a record year for orphan therapies
Trikafta/Kaftrio continues to be a game-changer for cystic fibrosis patients
Mimotopes Company Insight
Mimotopes
In Depth
Mapping the RNA therapeutics R&D landscape in 2022
A cloudy day in paradise for pharma tax havens in Cayman Islands & Bermuda?
Pharmaceutical Technology Excellence Awards 2021 – Winners Announced!
How technology could transform drug research in 2022
Anaesthesia drugs worst-hit by US drug shortages
Molnar-Institute Company Insight
Molnar-Institute
In Data
Asia-Pacific sees the largest growth in metabolic disorders-related trials over
The Middle East has seen the largest growth in infectious disease-related trials over the past decade
Global markets and indices
Macro-economic indicators
Macro-economic indicators (page 2)
Baxter
Events
Next issue

01/20/2022 00:00:00